NATHBIOGEN Stock Overview
Engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Nath Bio-Genes (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹194.20 |
| 52 Week High | ₹264.31 |
| 52 Week Low | ₹167.15 |
| Beta | 1.36 |
| 1 Month Change | 10.44% |
| 3 Month Change | -9.33% |
| 1 Year Change | -3.98% |
| 3 Year Change | -22.84% |
| 5 Year Change | -42.44% |
| Change since IPO | 824.76% |
Recent News & Updates
Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Dec 03
Here's Why Shareholders Should Examine Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) CEO Compensation Package More Closely
Aug 11Recent updates
Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Dec 03Here's Why Shareholders Should Examine Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) CEO Compensation Package More Closely
Aug 11Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Solid Earnings May Rest On Weak Foundations
Jul 31Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Shares Fly 34% But Investors Aren't Buying For Growth
Jul 02These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Jun 27Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has More To Do To Multiply In Value Going Forward
Apr 05Returns On Capital At Nath Bio-Genes (India) (NSE:NATHBIOGEN) Have Hit The Brakes
Oct 24Nath Bio-Genes (India) (NSE:NATHBIOGEN) Seems To Use Debt Quite Sensibly
Aug 05Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has Some Way To Go To Become A Multi-Bagger
Jun 07Some Investors May Be Worried About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Feb 11We Think Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Taking Some Risk With Its Debt
Aug 27Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital Not Reflecting Well On The Business
Jun 19Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has A Pretty Healthy Balance Sheet
Feb 24Returns On Capital Signal Tricky Times Ahead For Nath Bio-Genes (India) (NSE:NATHBIOGEN)
May 27Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Feb 28The Trends At Nath Bio-Genes (India) (NSE:NATHBIOGEN) That You Should Know About
Feb 07Declining Stock and Decent Financials: Is The Market Wrong About Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)?
Jan 19The Nath Bio-Genes (India) (NSE:NATHBIOGEN) Share Price Is Up 149% And Shareholders Are Boasting About It
Jan 01Why Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay Matters
Dec 14
These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Nov 26Here's What To Make Of Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Nov 05Do Its Financials Have Any Role To Play In Driving Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) Stock Up Recently?
Oct 15Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Might Not Be As Mispriced As It Looks After Plunging 25%
Sep 24Many Still Looking Away From Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)
Sep 08Introducing Nath Bio-Genes (India) (NSE:NATHBIOGEN), The Stock That Soared 311% In The Last Five Years
Sep 07Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Doing What It Can To Lift Shares
Aug 18Here's What We Think About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay
Jul 26Shareholder Returns
| NATHBIOGEN | IN Food | IN Market | |
|---|---|---|---|
| 7D | -2.3% | -2.4% | -1.9% |
| 1Y | -4.0% | 4.8% | 24.7% |
Return vs Industry: NATHBIOGEN underperformed the Indian Food industry which returned 4.8% over the past year.
Return vs Market: NATHBIOGEN underperformed the Indian Market which returned 24.7% over the past year.
Price Volatility
| NATHBIOGEN volatility | |
|---|---|
| NATHBIOGEN Average Weekly Movement | 4.0% |
| Food Industry Average Movement | 6.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: NATHBIOGEN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: NATHBIOGEN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 423 | Satish Kagliwal | nathbiogenes.com |
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; seeds for field crops, such as bajra, corn, paddy, wheat, and jowar; fruit seeds; and seeds for vegetables comprising chilli, onion, okra, tomato, brinjal, bottle gourd, bitter gourd, sponge gourd, ridge gourd, cucumber, coriander, sweet pepper, green peas, pumpkin, tinda, cabbage, and French beans.
Nath Bio-Genes (India) Limited Fundamentals Summary
| NATHBIOGEN fundamental statistics | |
|---|---|
| Market cap | ₹3.67b |
| Earnings (TTM) | ₹393.73m |
| Revenue (TTM) | ₹3.51b |
9.4x
P/E Ratio1.1x
P/S RatioIs NATHBIOGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NATHBIOGEN income statement (TTM) | |
|---|---|
| Revenue | ₹3.51b |
| Cost of Revenue | ₹923.16m |
| Gross Profit | ₹2.59b |
| Other Expenses | ₹2.19b |
| Earnings | ₹393.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 20.72 |
| Gross Margin | 73.70% |
| Net Profit Margin | 11.22% |
| Debt/Equity Ratio | 19.9% |
How did NATHBIOGEN perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield10%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 12:00 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nath Bio-Genes (India) Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |